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Molecular markers such as mutational spectra or mRNA expression patterns may give some
indication of the mechanisms of carcinogenesis induced by fibers and other carcinogens. In our
study, tumors were induced by application of crocidolite asbestos or benzo[alpyrene (B[a]P) to rat
peritoneum. DNA and RNA of these tumors were subjected to analysis of point mutations and to
investigation of mRNA expression patterns. With both assays we found typical features
depending on the type of carcinogen applied. The analysis of point mutations in the tumor
suppressor gene p53 revealed mutations in the B[a]P-induced tumors. However, in the tumors
induced by crocidolite asbestos that were of the same tumor type as those induced by B[alP,
mutations in p53 were not detectable. Every mutation detected on the DNA level causes an
amino acid substitution within one of the functional domains of the tumor suppressor protein.
Therefore, these mutations seem to be of biological relevance for tumor progression and indicate
a difference in the carcinogenesis regarding the type of the carcinogenic substance. An additional
specificity of crocidolite-induced tumors was detectable by analyzing the mRNA expression of the
tumor suppressor gene WT1, which is known to be expressed in human mesothelial and
mesothelioma cells. A relatively high amount of WT1 mRNA was measured by quantitative
competitive reverse transcription-polymerase using RNA extracted from crocidolite-induced
tumors. However, WT1 seems to be expressed on a rather low level in tumors induced by B[a]P.
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Introduction
Tumors can be induced in the peritoneal
cavity ofrats by application offibrous dusts.
These tumors arise from mesothelial cells
and are histologically comparable with the
mesotheliomas induced by fibers in human
pleura (1). This experimental system ofip
injection has been used as a very sensitive
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assay for the assessment of fiber carcino-
genicity (2,3). Since the general mechanism
of tumor induction by fibers is still not
understood, the relevance of the data
obtained in the animal experiments used to
assess fiber carcinogenicity in humans is
discussed in depth (4). Therefore, it is
important to elucidate the mechanisms of
fiber carcinogenesis. Molecular characteriza-
tion ofthe tumors induced by fibers in rats
may help in comparing them with tumors
occurring in humans.
The investigation of oncogenes and
tumor suppressor genes may provide infor-
mation about tumor characteristics and the
mechanisms of carcinogenesis induced by
fibers. Mutational spectra ofthe p53 gene
can give information about the way
carcinogenic substances interact with the
DNA (5,6). Most of the mutations that
inactivate gene function occur within
five functional domains of the gene
(I-V) that contain the information for the
DNA-binding activity of the protein (7).
The position and type ofmutation (transi-
tion or transversion) can leave a "molecular
footprint" on the DNA (8). One hypothe-
sis concerning the carcinogenic effect of
fibers is based on the involvement of reac-
tive oxygen metabolites (9). Reactive oxy-
gen species (ROS) may be released by
macrophages that accumulate in chronic
inflammatory processes induced by fibers
(10,11). A reaction of ROS with DNA
may result in the generation ofpoint muta-
tions and therefore may be the cause of
well-defined point mutations in p53, as
described for H202 (12). p53 is well
known as a regulator ofthe cell cycle (13)
as well as a protein that is activated and
accumulated when DNA-damaging agents
are applied (14). The occurrence of point
mutations inp53 and the differences in the
expression levels of this tumor suppressor
may be a typical feature of a tumor type
and may give insight into the development
ofa malignant tumor.
Point mutations in p53 and the
expression of p53 mRNA in cultured
human mesothelioma cells have been inves-
tigated in two studies (15,16). Collectively
the results showed that the occurrence of
point mutations in p53 seems of minor
importance in human mesotheliomas com-
pared with other human tumor types.
These results, however, preclude a state-
ment about the potential offibers to induce
point mutations. In the case of human
mesothelioma, p53 may not be the appro-
priate target for mutations to occur .
The Wilms' tumor suppressor gene
(WTI) coding for a DNA-binding zinc fin-
ger protein was first identified by its muta-
tional inactivation in cases of Wilms'
tumors (17-19). The normal expression
pattern in several fetal and adult meso-
derm-derived tissues exhibits variations in
the amount of mRNA from four possible
splicing variants (20). WTI expression can
be observed in mesothelial cells from
humans, mice, and rats, as well as in
pleural mesothelioma cells from humans
and rats (21,22). In one case of human
mesothelioma, a mutation in WTI was
observed that converted the protein func-
tion from a transcriptional repressor into a
transcriptional activator (21). Walker et al.
(22) suggest usingWTJ expression as a
diagnostic marker to distinguish mesothe-
lioma from other tumors occurring in the
pleural cavity.
This study compares molecular features
such as p53 mutations, as well as mRNA
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expression ofp53 and WTI in rat mesothe-
lioma induced by fibers and a chemical car-
cinogen, to find typical features for
fiber-induced carcinogenesis. In addition,
similarities to or differences from the
human system may allow us to evaluate the
experimental system offiber administration
by ip injection in rats. To this end, tumors
induced by ip injection of crocidolite
asbestos and benzo[a]pyrene (B[a]P) were
subjected to analysis ofmutations inp53by
denaturing gradient gel electrophoresis
(DGGE) and DNA sequencing, and to
analysis ofp53and WTJ mRNAexpression
by competitive reverse transcription-
polymerase chain reaction (RT-PCR).
Material and Methods
AnimalExperiment
Three groups of rats (Wistar Wi/Wu,
Kissleg, Federal Republic of Germany)
were treated by ip injection as described
for the experiments reported by Roller et
al. (4). Crocidolite asbestos (South
Africa) (23) was administered in a 2-mg
dose per animal. Each dose was suspended
in 2 ml of0.9% NaCl solution. Five mil-
ligrams ofB[a]P was injected with a carrier
substance (1.5 ml beeswax/tricapryline
20:80) not known to induce tumor rates
any higher than those in nontreated ani-
mals. Control animals were treated with 2
ml of0.9% NaCl solution. Animals were
sacrificed after they exhibited visible health
impairment. Their peritoneums were
opened and tissue samples ofmacroscopi-
cally visible tumors, as well as ofseveral
other tissues, were taken. Each sample was
divided into two parts. One part was
frozen in liquid nitrogen and kept at
-70°C for later preparation of genomic
DNA and total RNA. The other part was
fixed in formalin and embedded in paraffin
for histologic investigations as described by
Friemann et al. (24).
DNAPrepartion
DNA extraction of tumor and nontumor
tissue was performed according to a com-
mercially available DNA extraction kit
(Stratagene, LaJolla, CA).
DNA Amplification by Polymerase
Chain Reaction. Genomic DNA (50 ng)
was amplified in a first polymerase chain
reaction (PCR) using the following primer
combinations: p53IIRL/p53IIbRR (halfof
domain II and domain III);p53RL/p531RR
(domain IV); andp532RL/p53RR (domain
V) (25). Amplified DNA fragments
contained intron sequences or the primers
were selected to anneal within introns to
ensure that sequences ofpseudogenes that
may exist in the rat genome were not
amplified or could be discriminated.
Primer sequences were p53IIRL 5'-CTTG
TCCGCTACTTTGATTCT-3'; p53IIbRR
5'-TGGAAACCAGTTCTAACCCCACA-3';
p53RL 5'-TCCGACTATACCACTATCC
AC-3';p53JRR 5'-CCAAGATGCCACAGA
GATAAGA-3'; p532RL 5'-GGATGGAGC
CCAGCTTCTTTACT-3'; p53RR 5'-AGC
TCCGGGCAATGCTCTTCTT-3'. In each
PCR one ofthe primers contained an eight-
base attachment site at the 5' end for subse-
quent incorporation ofa GC clamp (26).
Standard PCR conditions using a hot start
technique were 30x45 sec at 940C, 45 sec
at 50°C, 1 min at 72°C for the PCR with
p53IIRL/p53IIbRR andp53RL/p531RR for
p532RLJp53RR PCR conditions were simi-
lar except for the annealing temperature (1
min at 55°C). Attachment ofthe GC damp
was accomplished by reamplifying aliquots
ofPCR products according to Sheffield et
al. (26). To generate heteroduplex mole-
cules after PCR, we performed a denaturing
step of10 min at 95°C and an annealing by
continuously cooling to room temperature
over 30 min. PCR products were precipi-
tated and subsequently resolved in 10 mM
Tris-Cl, pH 8, 1 mM EDTA; approxi-
mately 100 ngwere analyzed by DGGE.
Denaturing Gradient Gel Electro-
phoresis. Five percent polyacrylamide gels
with a gradient ranging from 20 to 80%
denaturing agents parallel to the direction of
electrophoresis [100% denaturant: 7 M
urea/40% formamide; (27)] were run at
60°C with 2000 Vh (p53IIRL/p53IIbRR
and p532RL/p53RR), or 3200 Vh (p53-
RL/p53JRR). DNA was made visible by a
silverstaining method (28).
SequenceAnalysis. Templates for the
sequencing reactions were generated in a
separate PCR with the above-mentioned
primer combinations lacking the attach-
ment region. Direct sequencing ofthe PCR
products was performed by modification of
the dideoxy chain termination method of
Sanger et al. (29) usingthe PCRprimers.
RNAPreparaionandCompetitive
Polymerase Chain Reaction
Preparation oftotal RNA was performed
according to Chomczynski et al. (30). Rat
p53 cDNA fragment (219 bp) containing
domains IV and V were amplified using
p53RLandp53RR A competitive reference
standard (CRS) with a deletion of 50 bp
was constructed as described (31). Using
the same technique, a rat 3-actin CRS (246
bp) lacking 41 bp and a WTI CRS ampli-
fied from the shorter splice variant ofalter-
native splice I (131 bp) lacking 13 bp were
generated. Primers for /-actin are Act3'5'-
GGGCCGGACTCGTCATACTC-3'\ and
Act5'5'-TGTGGCATCCACGAAAC
TAC-3'. Primers for W/T1 alternative splice
I are 106 and 26 according to Haber et al.
(20) with the species-specific sequence
changes. In additional PCR the three frag-
ments were subsequently linked to obtain
internal standards that can be used in iden-
tical concentrations in separate PCR for
WTI and /-actin (32). RT-PCR was per-
formed as described (33) with 0.25 fmol
CRS and 5 x 10-2 to 5 x 10-5 dilutions (8
steps) of the cDNA. PCR products were
run on 10% polyacrylamide gels with
1 x0.9 M Tris-borate, 0.002 M EDTA,
pH 8. Quantification was performed after
staining with ethidium bromide and pho-
tographic documentation. After validation
of the method by scanning gel images
using a OmniMedia Scanner XRS and a
BioImager System (Millipore, Ann Arbor,
MI), band intensities were compared visu-
ally. In the case of WTJ, the intensity of
the 131-bp band was compared to the
internal standard molecule. Semiquan-
titative RT-PCRs were performed under
almost similar conditions. No CRS was
added in these reactions and the amplifica-
tion was performed with 25 to 28 cycles
(data not shown). Primers for HPRTwere
HPRT5' 5'-GCTGGTGAAAAGGAC-
CTCT-3' and HPRT3' 5'-ACAGGACTA-
GAACGTCTGC-3').
Results
An animal experiment was performed to
provide tumors for mutational analysis and
mRNA expression analysis. Tumors were
induced by ip injection of crocidolite
asbestos or B[a]P in separate groups. The
control group was treated with physiologic
NaCl solution. Table 1 summarizes the
tumor data obtained from the three experi-
mental groups. The distinction between
induced and spontaneous tumors was
made according to Roller et al. (4). The
results ofthe histopathologic investigations
on these tumors are published elsewhere
(24). There were no differences in the
morphologic differentiation ofthe tumors
among the samples from animals treated
with different carcinogens.
As a prescreening assay, we chose
DGGE which is well known as a reliable
method for rapid detection ofpoint muta-
tions (34). The heteroduplex-DGGE we
applied uses a GC clamp on one side ofthe
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Table 1. Abdominal tumors and corresponding p53mutations.
Tumors examined Tumors exhibiting
Rats with tumors Rats with peritoneal for point mutations point mutations Point mutations
Dose injected Number of assessed as non- tumors assessed as by DGGEand DNA in p53detected detected by
Treatment ip, mg rats treated treatment related treatment related sequencing by DGGE DNAsequencing
Crocidolite
asbestos 1x2 48 2a 29 24b 0 0
B[a]P 1x5 48 34 30b 8c 8c
NaCI, 0.9% 1x2ml 48 3d 0 2 1 1
"One liver carcinoma, one uterine carcinoma. bTumors assessed as treatment related. cp=0.006 compared to the crocidolite group (Fisher's exacttest). dTwo uterine carcino-
mas, one ovarian carcinoma.
PCR product and detects mismatched base
pairs (26). The GC damp ensures the par-
tial denaturation and the formation ofa Y-
shaped structure ofthe DNA double-strand
during electrophoresis on a gel containing a
denaturing gradient. The migration velocity
ofthese Y-shaped molecules decreases and a
banding at the corresponding concentration
ofdenaturing agents takes place. Because of
wild-type sequences that are present in our
PCR and denaturing and reannealing steps
after PCR, the amplification ofmutated
sequences results in formation of a DNA
double-strand containing at least one base
pair that is mismatched. The mismatched
base pair causes a melting behavior that dif-
fers significantly from that of the DNA
without a mismatched base pair (27).
Examples for the three different PCR prod-
ucts used for the examination ofthe p53
functional domains are shown in Figure 1.
In the analysis ofdomains II/III and IV,
both homoduplices and the two heterodu-
plices are visible as separate bands. Only one
band for both homoduplices is visible in the
case ofthe point mutation in domain IV in
DNAfrom animal T212/93. Here the melt-
ing temperature ofthe homoduplices does
not differ. For most tumors, several DNA
T225/93 T212/93 T204/93
T N N T N T _flsv§Ww: < 120%
Domains 11/Ill Domain IV Domain V 180%
Figure 1. DGGE of p53fragments covering the highly
conserved domains. PRC products from DNA of tumor-
ous (T) and nontumorous (N) tissues are compared.
The arrow on the right indicates the gradient of dena-
turing agents in the gel. Bands occurring in addition to
those ofthe Nsamples refer to mismatched base pairs
and indicate point mutations in the DNA fragments
investigated.
samples from different parts ofthe tumor
were prepared and examined. In addition,
one sample ofnontumorous tissue (mostly
liver) from each animal was analyzed.
Interestingly, we found eight point muta-
tions in the tumors induced by B[a]P,
whereas no mutations were detectable in
the crocidolite group (Table 1). A point
mutation occurred in one carcinoma ofthe
ovary from the control group (a tumor type
that was not examined in the B[a]P and
crocidolite groups).
Sequence analysis was performed to
determine the type and the exact position
of the point mutations and to verify the
method ofDGGE. DGGE was verified by
sequencing 37 DNA fragments that
exhibited no additional bands in the
DGGE (data not shown). In these DNA
samples no mutations were detectable by
sequence analysis and, conversely, every
mutation occurring in the DGGE resulted
in an altered DNA sequence in the
sequencing analysis. Sequencing reactions
were performed with newly amplified
DNA fragments to ensure that errors of
the Taq polymerase did not cause false
positives. Only mutations occurring in
both assays were assessed to be positive.
Table 2 summarizes the locations and the
types of the mutations found with both
assays. Obviously, all mutations observed
result in the substitution ofan amino acid
or, as in one case, in the formation of a
stop codon.
To analyze the expression of p53
mRNA and WTI mRNA competitive
RT-PCR using an internal mimic mole-
cule, CRS, was performed. As a positive
control for RT-PCRand to test the quality
ofthe RNA, the amount of,¢actin mRNA
was determined for each RNA sample. An
additional positive control was made by
measuring HPRT mRNA expression.
Semiquantitative RT-PCRs for P-actin
and HPRTwere compared. Expression lev-
els ofboth housekeeping genes correlated
well (data not shown). Examples ofquan-
tifications of,B-actin and WT1 cDNA ofa
B[a]P- and a crocidolite-induced tumor
are depicted in Figure 2. The results
obtained from mRNAs of 14 tumors
induced by B[a]P and of9 tumors induced
by crocidolite asbestos are summarized in
Table 3. Obviously, p53 mRNA can be
detected in all ofthe samples investigated
regardless of the tumor-inducing agent.
However, the amount of mRNA varies
from approximately 1 to 100 fmol/pg
RNA. In the tumors with mutations in the
p53 gene, mRNA transcribed from this
gene is detectable in considerable amounts.
An additional sequence analysis of the
amplified cDNA ofthese tumors showed
that the mRNA sequence refers to the
mutated type (data not shown). Results
from WTJ expression analysis revealed low
amounts of WT1 cDNA, ranging from 1
to 5 fmol/lig RNA in the B[a]P group.
However, in the crocidolite group, except
Table2. Results ofp53sequence analysis.
Carcinogen Animal no. Codon position Mutation Aminoacid substitution
Benzo[alpyrene T201/93 271 G-Atransition Arg-His
Benzo[a]pyrene T203/93 266 G-Ttransversion Asp-Tyr
Benzo[a]pyrene T204/93 263 G-Ttransversion Gly-Stop
Benzo[a]pyrene T208/93 269 A-G transition Glu-Gly
Benzo[alpyrene T212/93 250 C-G transversion lIe-Met
G-Ttranversion Arg-lle
Benzo[alpyrene T217/93 278 A-G transition Arg-Met
Benzo[a]pyrene T222/93 278 A-G transition Arg-Gly
Benzo[alpyrene T225/93 156 G-Atransition Arg-His
Control T683/93 139 T-Atransversion Cys-Ser
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T310/93
2 3 4 5 6 7 8
I 2.5fmol/gg RNA
1 2 3 4 5 6 7 8
oi
10fmol/,ug RNA
Figure 2. Competitive RT-PCR ofA3-actin and WT1 mRNA. Dilutions of cDNA were amplified under co
conditions in the presence of a mimic molecule (CRS). The lower bands refer to the CRS. In WT1-PCRs t
referring to the alternative splice are visible. Band intensities reflect the molar ratio of cDNA and Cl
onset ofthe PCR. T200/93, tumorfrom a B[a]P-treated animal. T310/93, tumorfrom a crocidolite-treated E
Table 3./3-Actin, p53, and WT1 mRNA amounts measured bycompetitive RT-PCR.
,¢ActincDNA, p53cDNA, WT1
Carcinogen Animal number fmol/pg fmol/pg RNA fmol)
Benzo[alpyrene T1 99/93 35 35
Benzo[a]pyrene T200/93 5 7.5
Benzo[a]pyrene T201/93a 35 35
Benzo[a]pyrene T202/93 2.5 2.5
Benzo[a]pyrene T203/93 a 75 100
Benzo[alpyrene T204/93a 10 7.5
Benzo[a]pyrene T208/93 a 25 75
Benzo[a]pyrene T209/93 35 1
Benzo[a]pyrene T212/93a 35 50
Benzo[a]pyrene T217/93 a 50 50
Benzo[alpyrene T218/93 75 50 1
Benzo[a]pyrene T219/93 10 35
Benzo[a]pyrene T222/93 a 10 35
Benzo[alpyrene T225/93 a 50 35
Crocidolite asbestos T295/93 75 10
Crocidolite asbestos T300/93 5 35
Crocidolite asbestos T303/93 5 5
Crocidolite asbestos T305/93 2.5 5
Crocidolite asbestos T309/93 35 0.5
Crocidolite asbestos T310/93 2.5 4
Crocidolite asbestos T317/93 50 50
Crocidolite asbestos T318/93 2.5 35
Crocidolite asbestos T321/93 50 5
ND, not determined. "RNA from tumorous tissue with detected mutations in p53. bHigh expression level
mRNA in crocidolite-induced tumors.
in one tumor, relatively high amounts
above 10fmol/pg RNA can be observed.
Discussion
Analysis of mutations in the tumor
suppressor gene p53 in tumors induced by
ip injection of B[a]P and croc
asbestos revealed significant diff
depending on the kind of carc
applied. All mutations detected
B[a]P-induced tumors resulted
stitutions of an amino acid or
formation of a stop codon that leads to
truncated mRNA molecules (Table 2).
The sequencing analysis of the RT-PCR
products showed that the mutant mRNAs
are detectable in these tumors. These
,-Actin results suggest that in these tumors the
mutant p53 tumor suppressor molecule
leads to an escape from cell cycle control
mediated by the wild-type p53 molecule
(35). Mutation ofp53 seems to be a com-
mon event in the tumorigenesis of this
tumor type when it is induced by B[a]P.
Interestingly, in tumors induced by crocido-
lite asbestos, no p53 point mutations were
detectable (Table 1). Since a large number
of tumor samples was examined and the
reliability of the DGGE prescreening
method could be demonstrated, we can
consider this result representative of
tumors induced by ip injection in rats.
Spontaneously occurring mutations,
mostly C-T transitions that arise from
mpetitive spontaneous deamination of naturally
wo bands occurring 5-methylcytosin residues (36),
RS at the also were not detectable in our fiber-
animal. induced tumors. This result may be of
interest with regard to the problem ofcar-
cinogenesis induced by mitogenic sub-
stances. Several publications discussed
cDNA, controversially a mechanism ofcarcinogen-
/pg RNA esis induced by proliferation-inducing
1 agents (37-39). Asbestos (or fibers in gen-
2.5 eral) is sometimes classified as a mitogeni-
5- cally acting carcinogen (37). The rationale
1 for this is that because ofthe high replica-
1 tion rate induced by this kind ofsubstance,
2.5 naturally occurring mutations accumulate
2.5 in the exposed tissue. The probability of 2.5 spontaneous mutations should rise with
1 the increase ofcell divisions, as observed in
ND tumor proliferation. In this case, we would
1 have expected at least a low frequency of
1.75 spontaneous p53 mutations in the croci-
1 dolite group. If we hypothesize a high
75b amount ofcell proliferation in all tumors
355b regardless of the kind ofinducing agent,
job our results show that-at least forp53 in
0.5 this experimental system-there is no
1job indication ofsuch a mechanism.
50b The complete lack ofp53 mutations in
job the crocidolite-induced tumors may also be
75b explained by differences in the mechanisms
Is of WT1 involved in tumor development. Kinzler
and Vogelstein (40) suggested, interpreting
p53 expression and mutation data from
idolite tumor cells under hypoxia according to
erences Graeber et al. (41), that under certain con-
inogen ditions in a developing tumor, p53 may be
in the induced and cell cycle control may then be
in sub- mediated by the p53 tumor suppressor
in the - protein. In this situation, cells-bearing
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mutations in p53 escape from the cell-cycle
control and achieve a growth advantage.
We hypothesize that in our experimental
system such a mechanism that induces p53
expression, may take place in the tumors
induced by B[a]P. However, in the tumors
induced by crocidolite asbestos, the escape
from cell-cycle control may be mediated by
another mechanism not involving p53. In
this case, the mutations observed would be
the result ofa selection mechanism due to
induction ofp53 in a certain stage oftumor
development. On the other hand, in the
crocidolite group no point mutations
attributable to this selection mechanism
could be detected.
In human mesotheliomas, p53 muta-
tions are ofminor importance in this tumor
type (15,16). Mutations were detectable in
4 cases of24 cell lines. We believe the situa-
tion is similar in both systems offiber car-
cinogenesis. The lack ofmutations in the
animal system may be explained by the
well-defined experimental system. In
human samples, additional carcinogens
may have induced mutations in p53. It is
obvious that the mutational status ofp53
could be useful to distinguish whether
fibrous or nonfibrous agents caused a
tumor. However, for this kind ofdiagnosis
a large amount of data, especially from
human mesothelioma of patients with
well-known exposures, would be necessary.
Further carcinogen-specific features
could be detected by the analysis of the
WTI mRNA amount using competitive
RT-PCR. As in human mesotheliomas
and rat pleural mesotheliomas, we found
mRNA transcribed from this gene in all
tumors investigated (Table 3). Differences
in the amounts ofsplice variants could not
be observed (data not shown). However,
the extent ofmRNA differed between the
two experimental groups. In B[a]P-
induced tumors a relatively lower amount
of WTI mRNA was detected than in the
crocidolite-induced tumors. The biological
relevance of these differences may be
explained by some characteristics of the
WTJ zinc finger protein. The mRNA tran-
scription ofsome growth factors known to
be overexpressed in mesothelioma is nor-
mally repressed by binding of WVTI to the
gene consensus sequence EGRI (42,43).
In mesothelioma cells with WTI inacti-
vated by mutations, the expression ofthese
growth factors may be a growth stimulus
for the tumor cell (44). Because only a few
mesotheliomas with WITI are described in
the literature, this pathway oftumorigene-
sis apparently does not occur frequently.
Another feature of the WTI protein is its
affinity to p53. Both gene products can
form a heterodimer protein complex that
exhibits altered protein functions (45).
WTI then acts as a transcriptional activator
after binding to the consensus sequence of
the target gene. In the presence ofcertain
amounts of WTI protein, a stabilization of
p53 protein and an inhibition ofapoptosis
was observed (46). Further investigation of
the ip-induced tumors will determine
whether one of these mechanisms is in
force in fiber-induced tumors.
The results presented here show paral-
lels between human mesotheliomas and the
tumors induced by ip application ofcroci-
dolite asbestos in rats. In both systems p53
mutations seem to be of minor impor-
tance. Because of the positive results
revealed from the B[a]P-induced tumors,
the lack of mutations in p53 does not
appear to be a characteristic of the tumor
type mesothelioma. Moreover, a normal
p53 status may be a typical feature ofcroci-
dolite-induced carcinogenesis and possibly
offiber-induced carcinogenesis in general.
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